Published in:
01-12-2010 | Clinical Study – Patient Study
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
Authors:
Gentian Kaloshi, Monica Sierra del Rio, François Ducray, Dimitri Psimaras, Ahmed Idbaih, Florence Laigle-Donadey, Sophie Taillibert, Caroline Houillier, Caroline Dehais, Antonio Omuro, Marc Sanson, Jean-Yves Delattre, Khe Hoang-Xuan
Published in:
Journal of Neuro-Oncology
|
Issue 3/2010
Login to get access
Abstract
There is a growing evidence of using Temozolomide as upfront therapy for progressive low grade gliomas. No data exist on the efficacy of nitrosoureas as an alternative to radiotherapy in those patients who progress after Temozolomide. We retrospectively reviewed 30 patients with median age of 46 years. Twenty-one patients had pure oligodendrogliomas. Thirteen patients had a non-enhancing tumor at progression after Temozolomide. The chromosomes 1p/19q were co-deleted in 5 cases and retained in 10 cases. Response rate was 10% (3 minor responses achieved in non-enhancing tumors). Tolerance was acceptable (17% grade III and IV myelosupression). Median PFS was 6.5 months. Median OS from start of salvage treatment was 23.4 months. Tumors without contrast enhancement demonstrated a better prognosis than those with contrast enhancement both in term of PFS (P = 0.0003) and OS (P = 0.0006). Chromosomes 1p/19q codeletion was not predictive for objective response to salvage treatment but correlated with a better PFS (P = 0.02). In conclusion, salvage NU chemotherapy provide disappointing results in TMZ-pretreated low grade gliomas (LGG), which should be treated in priority by conventional radiotherapy especially in LGG that display contrast enhancement at progression.